Honeywell Files Registration Statement for Aerospace Spinoff Planned in 2026
Honeywell filed its Form 10 registration statement with the U.S. Securities and Exchange Commission for the planned spinoff of Honeywell Aerospace, which is slated to begin trading on the Nasdaq under the ticker "HONA" in Q3 of 2026. Meanwhile, MiniMed opened at $19.05 after pricing its 28M‑share initial public offering at $20, below its targeted $25–$28 range.LATEST IPOS AND DIRECT LISTINGS:MiniMedopened on March 6 at $19.05. The diabetes business subsidiary of Medtronicpriced its initial public offering of 28M shares of its common stock at $20.00, below the target range of $25.00-$28.00.Robinhood Ventures Fund Iopened on March 6 at $22 after pricing its initial public offering of 12,615,608 common shares of beneficial interest at an initial public offering price of $25.00 per share. RVI is a closed-end fund from Robinhoodthat provides retail investors exposure to a concentrated portfolio of private companies.PERFORMANCE:Prices as of 10 am ET on Monday, March 9 -MiniMed – up almost 3% at $18.98;Robinhood Ventures Fund I – up 2% at $21.45.RECENT IPOS TO WATCH:ARKO Petroleum, Solv Energy, AGIare already seeing coverage roll out, while Jaguar Uraniumis among stocks that could see new coverage this week as the quiet periods for banks that underwrote the companies' IPOs expire.UPCOMING IPOS:Upcoming IPO and direct listings expected include Studend Living EduVation, Liftoff, Cerebras Systems, PayPay, and OpenAI.Clickto see upcoming IPO calendar on TipRanks.Student Living EduVation -The companyfiled with the SEC for an initial public offering of 3.75M ordinary shares. The company stated, "We are offering 3,750,000 Ordinary Shares on a firm commitment basis. We anticipate that Offering price of the Ordinary Shares will be between $4.00 and $6.00 per Ordinary Share. The Resale Shareholders are also offering 5,880,000 Ordinary Shares to be sold pursuant to the Resale Prospectus. We are registering the Resale Shares pursuant to the Registration Rights Agreements we entered into with the Six Pre-IPO Investors on September 19, 2025... We will not receive any of the proceeds from the sale of the Ordinary Shares by the Resale Shareholders. Prior to this Offering, there has been no public market for our Ordinary Shares. We intend to apply to list our Ordinary Shares on the Nasdaq Capital Market under the symbol 'SDLV'... We are a Cayman Islands exempted company with limited liability with a principal place of business in Hong Kong through our wholly-owned subsidiary, Student Living Culture Technology Limited. We are a student living and referral of education advisory services provider operating under the "Student Living" brand in Hong Kong. Our mission is to transform student dormitories into incubators for learning, collaboration, and self-discovery, as well as fostering an ecosystem that nurtures future global talent, providing more than just a place to live."Liftoff Mobile announced that it has confidentially submitted a draft registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock. The total number of shares to be offered and the price range for the proposed offering have not yet been determined. The offering is subject to market and other conditions and the completion of the SEC's review process.Cerebras Systems– The company has filed confidentially for a U.S. initial public offering, The Information's Valida Pau and Katie Roof. The re-filing comes after a major sales pact with OpenAI, the authors note.PayPay Corporation- The company filed for an initial public offering of American depositary shares, or ADSs, and has applied to list the ADSs on the Nasdaq Global Select Market under the symbol "PAYP." The prospects filed with the SEC states, "As Japan's leading financial technology company, we are dedicated to our goal of becoming a digital finance platform for all... We launched this service in October 2018 and it rapidly expanded to become a nation-wide leading cashless payments ecosystem that had approximately 72 million PayPay registered users as of December 31, 2025, representing a penetration of 75% among 96 million smartphone users in Japan. With the acquisition of PayPay Card Corporation in October 2022, our platform evolved to a next-generation payments ecosystem, seamlessly integrating our code-based payment and credit card payment services through our PayPay app."OpenAI- The is accelerating its plans for a public listing as rivalry with Anthropic intensifies, now planning on listing in Q4 of this year, Berber Jin, Corrie Driebusch, and Kate Clark of The Wall Street Journal. OpenAI is holding discussions with Wall Street banks about a potential initial public offering and has hired several executives to oversee its finance team, sources told the Journal.SpaceX- Elon Musk is targeting mid-June for the timing of SpaceX's initial public offering, IPO, Ivan Levingston, Stephen Morris, and Mercedes Ruehl of The Financial Times, citing five people familiar with the matter. The company is looking to raise $50B at a valuation of $1.5T, the sources added.OTHER IPO NEWS:Honeywellannounced the filing of its Form 10 registration statement with the U.S. SEC for the planned spinoff of Honeywell Aerospace, which will trade on the Nasdaq under the ticker "HONA." The filing represents significant milestone toward Honeywell Aerospace becoming an independent public company in the third quarter of 2026.Opening Day" is The Fly's recurring series of stories on the latest initial public offerings, their performance, and upcoming IPOs.
Trade with 70% Backtested Accuracy
Analyst Views on MMED
About MMED
About the author

- Technology Showcase: MiniMed will present its latest MiniMed Go™ and MiniMed Flex™ systems at the American Diabetes Association's Scientific Sessions from June 5-8, aiming to alleviate the daily burden of diabetes through advanced automation and smaller designs, thereby enhancing the quality of life for patients.
- Clinical Data Release: The company will share emerging clinical data demonstrating the real-world impact of its connected solutions, particularly how the recently refreshed sensor portfolio improves blood glucose control, further solidifying MiniMed's leadership in diabetes technology.
- Interactive Experience: Attendees will have hands-on opportunities to explore the real-time SmartGuard™ automation of the MiniMed Flex™ system and the MiniMed Go™ smart insulin pen's memory, reminders, and recommendations, enhancing user understanding and acceptance of new technologies.
- Scientific Presentations: MiniMed will also showcase multiple posters covering the application effects of automated insulin delivery systems in diverse populations, emphasizing the sustained effectiveness of its 780G system in diabetes management, thereby furthering the company's influence in the healthcare sector.
- Technology Showcase: MiniMed will present its latest MiniMed Go™ and MiniMed Flex™ systems at the American Diabetes Association Scientific Sessions from June 5-8, aiming to alleviate the daily burden on diabetes patients through advanced automation and more compact designs, thereby enhancing patients' quality of life.
- Clinical Data Release: The company will share emerging clinical data demonstrating the real-world impact of its connected solutions, particularly highlighting the effectiveness of its recently refreshed sensor portfolio in improving patient health outcomes.
- Interactive Experience: Attendees will have hands-on opportunities to explore the real-time SmartGuard™ automation features of the MiniMed Flex™ system and the memory, reminder, and recommendation capabilities of the MiniMed Go™ smart insulin pen, further enhancing user experience.
- Industry Leadership: As a global leader in insulin delivery, MiniMed continues to advance diabetes treatment technologies in 80 countries, committed to helping patients manage diabetes more easily through an integrated ecosystem and high-quality service, showcasing its innovation and influence in the industry.
- Goldman Sachs Conference Participation: MiniMed will participate in a fireside chat at the 47th Annual Goldman Sachs Global Healthcare Conference on June 8, 2026, which is expected to attract investor attention and enhance the company's visibility in the healthcare technology sector.
- Live Webcast and Replay: The fireside chat is scheduled for 11:20 a.m. EDT, and MiniMed will provide a live webcast and replay on its Investor Relations website, ensuring broad investor engagement and information transparency.
- Global Leadership Position: As a global leader in insulin delivery technology, MiniMed offers innovative therapies in over 80 countries, continuously improving the quality of life for diabetes patients and showcasing its strong influence in the healthcare technology industry.
- Mission and Vision: MiniMed is committed to simplifying diabetes management through an integrated ecosystem of insulin delivery systems, continuous glucose monitors, and user-friendly apps, reflecting the company's long-term dedication to improving patient lives.
- Algorithm-Driven Outcomes: A randomized crossover study revealed that participants using the MiniMed™ 780G system with either the Simplera Sync™ or Instinct sensor achieved nearly identical glycemic control metrics, underscoring the algorithm's pivotal role in clinical outcomes and reinforcing the system's market position.
- Clinical Validation Data: The study demonstrated that time in range for participants was 79.1% with Instinct and 80.6% with Simplera Sync™, both exceeding the American Diabetes Association's international consensus targets, indicating the system's effectiveness and reliability in diabetes management.
- Real-World Evidence: Analysis of over 20,000 U.S. users of the MiniMed™ 780G system confirmed the algorithm's central role in maintaining strong glycemic control, further enhancing user confidence in the system's capabilities.
- Broad Market Prospects: MiniMed CEO Que Dallara emphasized the company's commitment to advancing the science of automated insulin delivery and building a comprehensive insulin delivery ecosystem, suggesting significant future market potential for diabetes management solutions.
- Study Consistency: A randomized crossover study demonstrated that participants using the MiniMed™ 780G system showed nearly identical glycemic control metrics with the Simplera Sync™ and Instinct sensors, achieving time in range of 79.1% and 80.6% respectively, indicating that the intelligence of the algorithm is the primary determinant of clinical outcomes.
- Clinical Validation: The study reported no cases of diabetic ketoacidosis or severe hypoglycemia among the 24 adult participants with type 1 diabetes during the six-week sensor usage period, further validating the safety and efficacy of the MiniMed™ 780G system.
- Real-World Evidence: An analysis of over 20,000 U.S. users of the MiniMed™ 780G system showed that users maintained strong glycemic control after transitioning to the Instinct sensor, reinforcing the algorithm's central role in diabetes management.
- Future Development Focus: MiniMed CEO Que Dallara emphasized the company's commitment to advancing the science of automated insulin delivery and building a seamless insulin delivery ecosystem to simplify diabetes management and enhance user experience.
- Goldman Sachs Bullish on Aevex: Goldman Sachs initiates coverage of Aevex (AVEX) with a Buy rating and a $34 price target, based on a 5.4X CY27 EV/Sales, indicating confidence in the company's unique position in the drone market and its growth potential.
- Citi Raises Broadcom Target: Citi raises Broadcom's price target from $475 to $500, applying a 20x multiple to FY28 EPS of $25, reflecting optimism about the company's earnings visibility and maintaining its status as the #1 semiconductor pick for 2026.
- JPMorgan Upgrades Braskem: JPMorgan upgrades Braskem to Overweight from Neutral, citing improved market fundamentals, tighter supply, and strengthened governance post-restructuring, which are expected to enhance profit margins in the chemical sector.
- Evercore Initiates Benitec Coverage: Evercore initiates coverage of Benitec Biopharma with an Overweight rating, highlighting significant upside potential in the rare disease market, suggesting promising investment opportunities ahead.










